An Analytical Monograph on Picankibart (IBI-112): A New-Generation IL-23p19 Inhibitor for Autoimmune Diseases

Executive Summary

Picankibart, also known by its research and development code IBI-112, is an investigational, subcutaneously administered, recombinant monoclonal antibody developed by Innovent Biologics.[1] As a new molecular entity, it represents a significant advancement in the class of targeted biologic therapies for autoimmune diseases. The agent is engineered to be a highly selective inhibitor of the p19 subunit of interleukin-23 (IL-23p19), a cytokine validated as a central pathogenic driver in a spectrum of immune-mediated inflammatory disorders.[3]

The clinical development program for Picankibart has yielded compelling data, most notably from the pivotal Phase 3 CLEAR-1 registrational trial in adult patients with moderate-to-severe plaque psoriasis. The study demonstrated exceptional efficacy, with over 80% of subjects achieving a 90% or greater improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) at week 16. This result, which met the study's primary endpoint with high statistical significance, positions Picankibart with a potential best-in-class efficacy profile.[2] A key differentiator for Picankibart is its highly convenient maintenance dosing regimen of once every 12 weeks (Q12W), which offers a substantial improvement in patient convenience and potential adherence compared to many established biologic therapies.[2]

Innovent Biologics is executing a robust lifecycle management strategy to maximize the therapeutic potential of Picankibart. Beyond its initial indication, the drug has demonstrated positive results in a Phase 2 study for moderately to severely active ulcerative colitis, signaling its potential as a treatment for inflammatory bowel disease.[3] Furthermore, a dedicated clinical program is strategically targeting the growing population of psoriasis patients who have had an inadequate response to prior biologic treatments, including IL-17 inhibitors.[11]

From a regulatory perspective, Picankibart has achieved a critical milestone. In September 2024, Innovent announced that the New Drug Application (NDA) for Picankibart for the treatment of moderate-to-severe plaque psoriasis was accepted for review by China's National Medical Products Administration (NMPA).[5] This marks the first IL-23p19 inhibitor independently developed by a Chinese enterprise to reach this advanced regulatory stage, underscoring its importance to the domestic pharmaceutical landscape.[5]

In conclusion, Picankibart is poised to emerge as a leading therapeutic option for IL-23-mediated diseases. Its profile is defined by a combination of potentially superior efficacy, exceptional dosing convenience, and a favorable safety profile that is consistent with the well-characterized IL-23 inhibitor class. Pending regulatory approval, Picankibart is set to address significant unmet needs for patients, initially in China, with the potential for future global development.

Pharmacological Profile and Mechanism of Action

Drug Class and Molecular Identity

Picankibart (IBI-112) is a humanized monoclonal antibody, classified as a new molecular entity within the therapeutic categories of anti-inflammatory and antipsoriatic agents.[4] It is also identified by the synonym "Anti-interleukin 23p19 subunit antibody".[3] The drug was independently developed by Innovent Biologics, a Chinese biopharmaceutical company, and is protected by proprietary intellectual property rights.[1]

The IL-23/Th17 Axis: The Therapeutic Target

To understand the function of Picankibart, it is essential to first understand its target: the Interleukin-23/T-helper 17 (IL-23/Th17) signaling pathway. This axis is now recognized as a cornerstone of the pathophysiology of numerous autoimmune diseases, including psoriasis and inflammatory bowel disease.[1] IL-23 is a heterodimeric cytokine composed of two subunits: a p40 subunit, which it shares with IL-12, and a unique p19 subunit.[14] The primary role of IL-23 is to promote the survival, proliferation, and pathogenic function of Th17 cells. These cells are a subset of T-helper lymphocytes that produce a range of pro-inflammatory cytokines, most notably IL-17A and IL-17F.[14] In psoriasis, this cascade leads to hyperproliferation of keratinocytes, recruitment of other inflammatory cells into the skin, and the formation of characteristic psoriatic plaques.[15] By targeting a key upstream regulator (IL-23) of this pathway, inhibitors like Picankibart can effectively quell the downstream inflammatory cascade.

It is critical to clarify the precise molecular target of Picankibart. A small number of sources incorrectly state that Picankibart targets IL-17A.[16] This information is factually inaccurate and is contradicted by the vast majority of primary and authoritative sources. The developer, Innovent Biologics, has consistently and explicitly stated in all corporate communications, press releases, and study descriptions that Picankibart is a selective inhibitor of the

p19 subunit of Interleukin-23 (IL-23p19).[1] This is further corroborated by preclinical scientific publications and specialized pharmaceutical databases.[3] Moreover, Innovent's strategic communications often highlight the advantages of IL-23p19 inhibition over IL-17 inhibition, clearly delineating them as distinct mechanistic classes.[1] Therefore, the definitive mechanism of action is the targeted inhibition of IL-23p19.

Molecular Mechanism of Action

Picankibart exerts its therapeutic effect through a highly specific and targeted mechanism. The monoclonal antibody is engineered to bind with high affinity and specificity to the IL-23p19 subunit.[1] Because the p19 subunit is unique to the IL-23 cytokine, Picankibart does not interfere with the related IL-12 pathway.

This binding physically obstructs the interaction between the IL-23 cytokine and its corresponding cell surface receptor complex on immune cells.[17] By preventing this crucial ligand-receptor binding, Picankibart effectively neutralizes the biological activity of IL-23. This blockade abrogates the downstream intracellular signaling cascade, which includes the phosphorylation of the Signal Transducer and Activator of Transcription 3 (STAT3) protein.[14] The inhibition of STAT3 phosphorylation prevents the activation of genes responsible for the differentiation and maintenance of pathogenic Th17 cells. Preclinical studies have confirmed that this mechanism leads to a significant reduction in the production of downstream pro-inflammatory cytokines, such as IL-17, from immune cells.[14] The net result is a potent and targeted anti-inflammatory effect that addresses a root cause of the disease process.[14]

Pharmacokinetics and Pharmacodynamics

The pharmacokinetic (PK) and pharmacodynamic (PD) profile of Picankibart was initially characterized in a first-in-human (FIH), randomized, double-blind, placebo-controlled, single-ascending-dose study (NCT04511624) conducted in 46 healthy Chinese volunteers.[23] This study provided the foundational data on the drug's absorption, distribution, metabolism, and excretion (ADME) properties, as well as its initial safety profile.

• Absorption and Bioavailability: Following a single subcutaneous (SC) injection, Picankibart is absorbed slowly, with the median time to reach maximum serum concentration (Tmax​) ranging from 4 to 10.5 days.[23]
• Distribution and Elimination: The drug exhibits a prolonged elimination phase, with a terminal half-life (t1/2​) ranging from 21.8 to 35.8 days.[23] This long half-life is a key feature of the molecule, intentionally engineered through mutations in the Fc fragment of the antibody to enhance its persistence in circulation, as demonstrated in preclinical models.[14]
• Dose Proportionality: The FIH study confirmed that Picankibart exhibits linear PK characteristics. Across the SC dose range of 5 mg to 300 mg, key exposure parameters such as maximum concentration (Cmax​) and the area under the concentration-time curve (AUCinf​) increased in a dose-proportional manner.[23]
• Safety in Healthy Volunteers: In the FIH study, Picankibart was found to be safe and well-tolerated. No serious adverse events (SAEs) or other clinically significant adverse events were identified following single SC or intravenous (IV) doses up to 600 mg.[23]

The pharmacokinetic profile is not merely a technical characteristic but is the direct scientific enabler of Picankibart's primary competitive advantage in the clinical setting. The deliberate engineering of the antibody for an extended half-life is the foundational reason it can be administered with a long dosing interval. This favorable PK profile allows for sustained therapeutic drug concentrations over a prolonged period, which directly translates into the once-every-12-week (Q12W) maintenance dosing regimen successfully validated in the pivotal CLEAR-1 trial.[2] This regimen, requiring only 5-6 injections per year, offers a significant improvement in convenience and potential for better long-term adherence compared to many mainstream biologics that require 7 to 16 injections annually.[2] Thus, the foundational PK science is the core driver of the drug's patient-centric value proposition and its commercial competitiveness.

The Picankibart Clinical Development Program: A Strategic Overview

The clinical development of Picankibart has been executed through a comprehensive and strategically designed program aimed at establishing its efficacy and safety across multiple autoimmune indications and diverse patient populations. The program's architecture reflects a sophisticated approach to both secure initial market entry and aggressively pursue market expansion into areas of high unmet clinical need.

The key clinical trials that form the foundation of the Picankibart development program include:

• Phase 1 (NCT04511624): The foundational FIH study in healthy volunteers, which established the initial safety, tolerability, and pharmacokinetic profile of the drug.[3]
• Phase 3 in Plaque Psoriasis (CLEAR-1 / NCT05645627): The pivotal, multicenter, randomized, double-blind, placebo-controlled registrational study. Enrolling 500 Chinese subjects with moderate-to-severe plaque psoriasis, this trial was designed to demonstrate superiority over placebo and serves as the basis for the initial NDA submission.[3]
• Phase 3 in Plaque Psoriasis (NCT06049810 / CTR20232958): A multicenter, randomized, double-blind, placebo-controlled study that incorporates a randomized withdrawal and retreatment phase. This trial is designed to provide critical data on the durability of response, long-term maintenance of efficacy, and the ability to recapture response after treatment interruption.[3]
• Phase 2 in Biologic-Experienced Plaque Psoriasis (NCT05970978): A multicenter, open-label study involving 152 patients who had previously experienced an inadequate response to other biologic therapies, predominantly IL-17 inhibitors. This study provided the initial proof-of-concept for Picankibart's efficacy in a difficult-to-treat, refractory population.[4]
• Phase 3 in Biologic-Switch Plaque Psoriasis (NCT06945107): A landmark, multicenter, randomized, double-blind, active-controlled Phase 3 study. This trial is designed to directly compare the efficacy and safety of switching to Picankibart versus continuing treatment with an IL-17 inhibitor in patients who have had an inadequate response to the IL-17 agent. It is the first study of its kind in China for this patient population.[3]
• Phase 2 in Ulcerative Colitis (NCT05377580): A multicenter, randomized, double-blind, placebo-controlled study in 150 patients with moderately to severely active ulcerative colitis (UC). This trial successfully established proof-of-concept for Picankibart in a major inflammatory bowel disease indication.[3]
• Crohn's Disease: The program is expanding further into inflammatory bowel disease, with an Investigational New Drug (IND) application approved in China, allowing for the initiation of clinical trials in this indication.[3]

The design of this clinical program reveals a sophisticated, two-pronged strategy for market entry and subsequent expansion. The first prong, market entry, is anchored by the CLEAR-1 trial. This study's design was focused on establishing overwhelming superiority against a placebo in a population of patients who were either treatment-naive to biologics or had failed conventional systemic therapies. The goal was to secure a "best-in-class" efficacy claim, exemplified by the greater than 80% PASI 90 response rate, to facilitate a strong market launch.

The second prong, market expansion and differentiation, is being pursued concurrently and aggressively. Innovent did not wait for initial approval to investigate the biologic-experienced population. The rapid sequence of a successful Phase 2 open-label study (NCT05970978) followed immediately by the initiation of a robust, active-controlled, head-to-head Phase 3 trial (NCT06945107) against the current standard-of-care (IL-17 inhibitors) demonstrates a significant strategic commitment. This approach is designed to secure a position for Picankibart not only as a first-line biologic but also as the preferred "rescue" or "switch" therapy for the substantial and growing number of patients who fail to achieve or maintain an adequate response to other biologics. This directly addresses a major unmet clinical need and has the potential to significantly expand the drug's addressable market beyond initial therapy.[11]

Efficacy Analysis in Moderate-to-Severe Plaque Psoriasis

The CLEAR-1 Registrational Trial (NCT05645627): A Landmark Success

The CLEAR-1 study is the cornerstone of the Picankibart clinical program for plaque psoriasis and the primary source of data supporting its NDA submission to the NMPA. It was a large-scale, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 500 Chinese subjects with moderate-to-severe plaque psoriasis.[7]

Study Design and Endpoints

Participants were randomized in a 1:2:2 ratio to receive either placebo or one of two Picankibart maintenance regimens. The treatment protocol consisted of an induction phase where all active-treatment subjects received a 200 mg subcutaneous injection of Picankibart at weeks 0, 4, and 8. This was followed by a maintenance phase where subjects received either 200 mg or 100 mg of Picankibart every 12 weeks.[2]

The co-primary efficacy endpoints, assessed at week 16, were designed to measure significant clinical improvement and were:

1. The proportion of subjects achieving a 90% or greater improvement from baseline in the Psoriasis Area and Severity Index score (PASI 90).
2. The proportion of subjects achieving a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear).[7]

Efficacy Results

The CLEAR-1 study successfully met both of its co-primary endpoints, demonstrating a rapid, profound, and statistically significant superiority of Picankibart over placebo at week 16.[2]

• PASI 90 Response: At week 16, 80.3% of subjects in the Picankibart group achieved a PASI 90 response, compared to only 2.0% of subjects in the placebo group (p<0.0001).[7] This result is particularly noteworthy, as CLEAR-1 was the first global Phase 3 registration study for an IL-23p19 class inhibitor to report a PASI 90 rate exceeding 80% at 16 weeks, highlighting the drug's potential for best-in-class efficacy.[2]
• sPGA 0/1 Response: At week 16, 93.5% of subjects treated with Picankibart achieved an sPGA score of clear or almost clear, compared to 13.1% of those receiving placebo (p<0.0001).[7]

In addition to the primary endpoints, the study also met all of its key secondary endpoints with high statistical significance. Picankibart demonstrated superiority over placebo in achieving PASI 75 (≥75% improvement), PASI 100 (100% improvement, or complete skin clearance), and sPGA 0 (clear skin). Furthermore, treatment with Picankibart led to a significant improvement in patients' quality of life, as measured by the proportion of subjects achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1, indicating no or minimal impact of the disease on their life.[5]

Long-Term Maintenance of Efficacy

A critical aspect of psoriasis treatment is the ability to maintain a high level of efficacy over the long term. Data from the CLEAR-1 trial demonstrated that the strong efficacy observed at week 16 was robustly maintained through one year of treatment.[2] In the maintenance arm where patients received 200 mg of Picankibart every 12 weeks, the following high response rates were observed at week 52:

• PASI 90: 84.9% of subjects maintained a PASI 90 response.[7]
• sPGA 0/1: 85.9% of subjects maintained an sPGA score of 0 or 1.[7]

These results underscore the durable and long-lasting efficacy of Picankibart with a convenient Q12W dosing schedule.

Table 1: Summary of Pivotal Efficacy Results from the CLEAR-1 Study (NCT05645627)
Endpoint	Picankibart (n=401)	Placebo (n=99)	Statistical Significance
Co-Primary Endpoints at Week 16
PASI 90 Response (%)	80.3	2.0	p<0.0001
sPGA 0/1 Response (%)	93.5	13.1	p<0.0001
Key Secondary Endpoints at Week 16
PASI 75 Response (%)	Met	Not Met	p<0.0001
PASI 100 Response (%)	Met	Not Met	p<0.0001
sPGA 0 Response (%)	Met	Not Met	p<0.0001
DLQI 0/1 Response (%)	Met	Not Met	p<0.0001
Maintenance Endpoints at Week 52 (200mg Q12W arm)
PASI 90 Response (%)	84.9	N/A	N/A
sPGA 0/1 Response (%)	85.9	N/A	N/A

Efficacy in Biologic-Experienced Populations: Addressing Unmet Needs

A significant challenge in the modern management of psoriasis is the occurrence of primary or secondary treatment failure in patients receiving biologic therapies. Innovent's clinical program for Picankibart has strategically addressed this unmet need by evaluating its efficacy in patients with an inadequate response to prior biologics.

Phase 2 Open-Label Study (NCT05970978)

This multicenter, open-label Phase 2 study enrolled 152 Chinese patients with plaque psoriasis who had been previously treated with other biologics. Of the 83 patients classified as having an inadequate response at baseline, 96.4% had been treated with IL-17 inhibitors.[12] The study's primary endpoint at week 16 was notably stringent, requiring patients to achieve both an sPGA score of 0 or 1 AND a Body Surface Area (BSA) involvement of less than 3%.[27]

The study successfully met its primary endpoint, with 48.2% of the inadequate responders achieving this composite goal at week 16.[12] Analysis of key secondary endpoints revealed further robust efficacy:

• sPGA 0/1 Response: A majority of patients (64.6%) with a baseline sPGA of ≥2 and BSA of ≥3% achieved an sPGA score of 0 or 1.[11]
• Complete Clearance (sPGA 0): A notable 18.1% of these patients achieved complete skin clearance.[11]
• Quality of Life: 38.0% of patients with a baseline DLQI score >1 achieved a score of 0 or 1, indicating a significant improvement in their quality of life.[12]

Phase 3 Active-Controlled Study (NCT06945107)

Building on the encouraging Phase 2 data, Innovent initiated a high-stakes Phase 3 trial (NCT06945107) to definitively establish Picankibart's role in the biologic-switcher population. This trial is a randomized, double-blind, active-controlled study that will directly compare the efficacy of switching to Picankibart versus continuing on an IL-17 inhibitor for patients who have demonstrated an inadequate response to the IL-17 inhibitor.[26]

This head-to-head trial design represents a significant strategic decision. Real-world evidence indicates that a substantial proportion of patients experience primary or secondary failure on existing biologics, creating a clear and urgent unmet need for effective subsequent treatment options.[26] The preceding Phase 2 study provided a strong signal that Picankibart could be effective in this refractory population. By investing in a rigorous, active-controlled Phase 3 study, Innovent is aiming to generate Level 1 evidence. A successful outcome would not just suggest that Picankibart is an alternative; it could prove that switching to Picankibart is clinically superior to continuing a failing IL-17 inhibitor therapy. Such a result would have the potential to directly influence clinical practice guidelines, positioning Picankibart as the recommended next-line therapy after IL-17 inhibitor failure and securing a large, well-defined segment of the psoriasis market.

Efficacy in Other Autoimmune Indications

Ulcerative Colitis (UC): A Promising New Frontier

Innovent has expanded the clinical development of Picankibart beyond dermatology into gastroenterology, with a focus on inflammatory bowel disease (IBD). The initial results from a Phase 2 study in ulcerative colitis have been highly promising.

Phase 2 Study Design and Results (NCT05377580)

This was a multicenter, randomized, double-blind, placebo-controlled Phase 2 study that enrolled 150 Chinese patients with moderately to severely active UC.[10] The study consisted of a 12-week induction period where patients were randomized in a 1:1:1 ratio to receive intravenous (IV) infusions of placebo, Picankibart 200 mg, or Picankibart 600 mg at weeks 0, 4, and 8.[29]

The primary endpoint was the proportion of subjects who achieved clinical remission at week 12, as defined by the modified Mayo score.[10]

The study successfully met its primary endpoint, with both Picankibart dose groups demonstrating statistically significant improvements in clinical remission rates compared to placebo (p<0.05) [10]:

• Clinical Remission at Week 12:
• Picankibart 200 mg group: 20.0%
• Picankibart 600 mg group: 14.0%
• Placebo group: 2.0%

Furthermore, Picankibart showed significant efficacy across key secondary endpoints, including clinical response (p<0.001), symptomatic remission, and endoscopic remission. The clinical response rates were particularly strong, indicating a broad therapeutic benefit.[10] The maintenance phase of the study, where subjects receive subcutaneous Picankibart, is ongoing, with early observations suggesting that clinical benefit continues to increase over time.[29]

Table 2: Efficacy Endpoints from the Phase 2 Study in Ulcerative Colitis (NCT05377580) at Week 12
Endpoint	Picankibart 200 mg IV	Picankibart 600 mg IV	Placebo IV
Clinical Remission (%)	20.0	14.0	2.0
Clinical Response (%)	54.0	68.0	22.0
Symptomatic Remission (%)	Higher than Placebo	Higher than Placebo	Baseline
Endoscopic Remission (%)	Higher than Placebo	Higher than Placebo	Baseline

Future Indications

The successful proof-of-concept in ulcerative colitis has paved the way for further expansion within IBD. Innovent has received Investigational New Drug (IND) approval in China to begin clinical development of Picankibart for the treatment of Crohn's disease, another major form of IBD.[3]

Comprehensive Safety and Tolerability Profile

Overall Assessment

Across its comprehensive clinical development program, which includes Phase 1 studies in healthy volunteers and Phase 2 and 3 studies in patients with plaque psoriasis and ulcerative colitis, Picankibart has consistently demonstrated a favorable safety and tolerability profile.[2]

Key Safety Findings

The safety data gathered to date have been reassuring and align with the known safety profile of the IL-23p19 inhibitor class of drugs.

• No New Safety Signals: A consistent finding reported across multiple clinical trials and press releases is that no new or unexpected safety signals have been identified with Picankibart treatment.[2] The overall safety profile is described as being similar to that of other IL-23p19 monoclonal antibodies.[17]
• Adverse Events (AEs): The adverse events observed have generally been mild to moderate in severity.
• In the Phase 2 study in plaque psoriasis, the most frequently reported treatment-emergent adverse event (with an incidence of ≥10%) was upper respiratory tract infection, which is a known class effect of interleukin inhibitors.[17]
• In the pivotal CLEAR-1 Phase 3 trial, the overall rate of treatment-emergent adverse events during the 16-week induction period was reported to be similar between the Picankibart and placebo groups, indicating that the drug did not lead to a significant increase in short-term AEs compared to placebo.[32]
• The safety profile remained favorable during the long-term maintenance period of the CLEAR-1 study, with no new concerns emerging up to 52 weeks of treatment.[25]
• Immunogenicity: The potential for patients to develop anti-drug antibodies (ADAs) is a standard assessment for all biologic therapies. The Phase 1 study protocol included the evaluation of immunogenicity, and while specific rates have not been detailed in the provided materials, the overall favorable safety profile suggests that immunogenicity has not been a significant clinical concern to date.[23]

Contraindications and Warnings

As Picankibart is an investigational drug that has not yet received regulatory approval, there is no official, finalized prescribing information that includes a list of contraindications and warnings. The available clinical trial reports do not specify any absolute contraindications identified during the studies.[3]

However, based on its mechanism of action and its membership in the IL-23 inhibitor class, it is reasonable to anticipate that the final product label will include class-specific warnings and precautions. The IL-23 pathway is involved in host defense against certain infections. Therefore, warnings for this class of drugs typically include:

• Infections: An increased risk of infections, particularly upper respiratory tract infections. Patients should be evaluated for active infections before starting therapy.[40]
• Tuberculosis (TB): Patients should be evaluated for latent or active tuberculosis infection prior to initiating treatment. Treatment for latent TB should be considered before starting Picankibart.[40]
• Vaccinations: The use of live vaccines during treatment with IL-23 inhibitors is typically not recommended.[40]

These anticipated warnings are standard for the therapeutic class and are not indicative of an unusual or unexpected risk profile for Picankibart.

Dosing, Administration, and Prescribing Information

Route of Administration

Picankibart is formulated for subcutaneous (SC) injection.[3] To enhance patient convenience and ease of use, Innovent is also developing an auto-injector for the administration of Picankibart.[1] For the induction treatment of ulcerative colitis, the drug has been studied as an intravenous (IV) infusion.[29]

Dosing Regimen

The dosing regimens for Picankibart have been established in its clinical trials for specific indications. As the drug is not yet approved, this information is based on the study protocols.

Plaque Psoriasis

The dosing regimen evaluated in the pivotal CLEAR-1 Phase 3 trial is as follows [2]:

• Induction Phase: A 200 mg dose administered by SC injection at Week 0, Week 4, and Week 8.
• Maintenance Phase: Following the induction phase, treatment continues with a 100 mg or 200 mg dose administered by SC injection once every 12 weeks (Q12W).

Ulcerative Colitis

The dosing regimen evaluated in the Phase 2 study is as follows [29]:

• Induction Phase: A 200 mg or 600 mg dose administered via intravenous (IV) infusion at Week 0, Week 4, and Week 8.
• Maintenance Phase: Following the induction phase, treatment continues with a 200 mg dose administered by SC injection every 4 or 8 weeks.

Prescribing Information

Official prescribing information is not yet available, as Picankibart is currently under regulatory review by the NMPA in China and has not been approved for commercial use in any jurisdiction.[20] The information presented in this report is derived from publicly disclosed clinical trial data and corporate communications.

Strategic Analysis and Market Positioning

Competitive Landscape Analysis

Picankibart is entering a competitive but highly valuable market for biologic therapies in autoimmune diseases. Its market positioning and potential for commercial success will be determined by its ability to differentiate itself from established and emerging competitors. The strategic positioning of Picankibart appears to be built upon two fundamental pillars: potentially superior efficacy and superior dosing convenience.

• Efficacy: The headline result from the CLEAR-1 trial—an 80.3% PASI 90 response rate at week 16—is a key differentiator.[2] This level of efficacy is positioned as a potential best-in-class outcome and compares favorably with the pivotal trial data of many leading biologics in psoriasis.[42] Achieving such a high level of skin clearance so rapidly is a powerful message for both clinicians and patients.
• Convenience: The once-every-12-week (Q12W) maintenance dosing regimen is arguably Picankibart's most significant competitive advantage.[2] This translates to only 5-6 injections per year for a patient, a marked improvement over the 7-16 injections required annually for many other mainstream biologics, including some anti-IL-17 and older anti-TNF agents.[2] This reduction in treatment burden is a major factor in improving long-term patient adherence and quality of life, which are critical considerations in the management of a chronic disease like psoriasis.[2]

Table 3: Comparative Profile of Picankibart vs. Key Competitors in Plaque Psoriasis
Drug (Brand Name)	Developer	Target	PASI 90 at ~16 Weeks (%)	Maintenance Dosing Frequency
Picankibart	Innovent Biologics	IL-23p19	80.3	Every 12 Weeks
Risankizumab (Skyrizi)	AbbVie	IL-23p19	~75	Every 12 Weeks
Guselkumab (Tremfya)	Johnson & Johnson	IL-23p19	~73	Every 8 Weeks
Ixekizumab (Taltz)	Eli Lilly	IL-17A	~73	Every 4 Weeks
Secukinumab (Cosentyx)	Novartis	IL-17A	~65	Every 4 Weeks

Note: Competitor data is based on publicly available information from their respective pivotal trials and is provided for general comparative purposes.[30] Direct head-to-head trial data is limited.

Regulatory and Market Access

The regulatory progress of Picankibart in China is a major value driver. The acceptance of the New Drug Application (NDA) by China's NMPA in September 2024 is a pivotal event that validates the quality and strength of the CLEAR-1 data package.[5] As the first IL-23p19 inhibitor to be independently developed by a domestic Chinese company and submitted for approval in China, Picankibart holds a unique position.[2] This may confer advantages in the regulatory review process and subsequent market access negotiations, including national reimbursement listings.

While the initial focus is on the Chinese market, the strength of the clinical data suggests that Picankibart has significant global potential. Future submissions to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are plausible next steps, should Innovent pursue international commercialization.[45]

Future Outlook and Unanswered Questions

The future trajectory of Picankibart appears highly promising, but several key questions remain that will be answered as the clinical program matures.

• The results of the head-to-head Phase 3 trial (NCT06945107) comparing Picankibart to an IL-17 inhibitor in biologic-experienced patients will be a major catalyst. A positive outcome could fundamentally reshape treatment algorithms for psoriasis.
• Long-term safety and efficacy data beyond the 52-week time point will be crucial for reinforcing the drug's durable and safe profile, which is essential for a chronic-use medication.
• The clinical development path and subsequent data in Crohn's disease will be critical in determining the full therapeutic and commercial potential of Picankibart as a franchise product in inflammatory bowel disease.
• There is currently a lack of publicly available data from dedicated drug-drug interaction studies. However, as a monoclonal antibody, Picankibart is not expected to be metabolized by cytochrome P450 (CYP) enzymes, and therefore, the risk of clinically significant pharmacokinetic drug-drug interactions with small molecule drugs is considered very low. This is a consistent finding for other therapeutic antibodies, including those used in psoriasis, such as secukinumab and guselkumab.[46] While formal study results are pending, this is considered a low-risk area.

Conclusion

Picankibart (IBI-112) has emerged from its clinical development program as a highly promising therapeutic agent for the treatment of autoimmune diseases. Developed by Innovent Biologics, this selective IL-23p19 inhibitor has demonstrated a compelling clinical profile characterized by a combination of high-level efficacy, long-term durability, and a favorable safety profile consistent with its class.

In its lead indication of moderate-to-severe plaque psoriasis, Picankibart has set a new potential benchmark for efficacy with its pivotal CLEAR-1 trial results. The achievement of over 80% of patients reaching PASI 90 at 16 weeks, coupled with a highly convenient once-every-12-week maintenance dosing schedule, establishes a powerful value proposition for both patients and clinicians. This combination of profound skin clearance and reduced treatment burden positions Picankibart to be a formidable competitor in the global biologics market.

The strategic foresight of Innovent's clinical development plan is evident in its concurrent pursuit of both first-line approval and a leadership position in the biologic-switcher setting. The ongoing head-to-head trial against IL-17 inhibitors could provide definitive evidence to guide treatment decisions for a challenging patient population, potentially securing a significant market segment. Furthermore, the successful expansion into ulcerative colitis validates Picankibart as a platform molecule with franchise potential across multiple immune-mediated inflammatory diseases.

With its New Drug Application now under review by the NMPA in China, Picankibart is on the cusp of becoming a major new treatment option. Its profile suggests it has the potential to not only capture significant market share but also to elevate the standard of care for patients suffering from debilitating autoimmune conditions.

Works cited

1. Press Release, accessed August 29, 2025, https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=373
2. Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA - BioSpace, accessed August 29, 2025, https://www.biospace.com/innovent-announces-picankibart-ibi112-achieved-primary-endpoints-in-a-phase-3-clinical-trial-in-treating-moderate-to-severe-plaque-psoriasis-and-plans-to-submit-nda-to-the-nmpa
3. Picankibart - Drug Targets, Indications, Patents - Patsnap Synapse, accessed August 29, 2025, https://synapse.patsnap.com/drug/9a18076a63c545ccb5e6f34ab81474c2
4. Picankibart - Innovent Biologics - AdisInsight - Springer, accessed August 29, 2025, https://adisinsight.springer.com/drugs/800059330
5. Press Release, accessed August 29, 2025, https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=486
6. Innovent Biologics Announces Phase 3 Success for Picankibart in Treating Moderate to SevereInnovent Biologics Announces Phase 3 Success for Picankibart in Treating Moderate to Severe Plaque Psoriasis - BioPharma APAC, accessed August 29, 2025, https://www.biopharmaapac.com/news/75/4812/innovent-biologics-announces-phase-3-success-for-picankibart-in-treating-moderate-to-severeinnovent-biologics-announces-phase-3-success-for-picankibart-in-treating-moderate-to-severe-plaque-psoriasis.html
7. Press Release, accessed August 29, 2025, https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=450
8. Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis - PR Newswire, accessed August 29, 2025, https://www.prnewswire.com/news-releases/innovent-announces-nmpa-acceptance-of-nda-for-picankibart-anti-il-23p19-antibody-for-treating-moderate-to-severe-plaque-psoriasis-302259367.html
9. NMPA Approves Innovent's Picankibart for Moderate to Severe Plaque Psoriasis Treatment, accessed August 29, 2025, https://synapse.patsnap.com/blog/nmpa-approves-innovents-picankibart-for-moderate-to-severe-plaque-psoriasis-treatment
10. Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint | IVBIY Stock News, accessed August 29, 2025, https://www.stocktitan.net/news/IVBIY/innovent-announces-phase-2-clinical-study-of-picankibart-ibi112-in-rgmyyjd08589.html
11. Press Release, accessed August 29, 2025, https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=491
12. Innovent's picankibart succeeds in mid-stage psoriasis study of biologic switchers, accessed August 29, 2025, https://firstwordpharma.com/story/5907403
13. Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis | IVBIY Stock News, accessed August 29, 2025, https://www.stocktitan.net/news/IVBIY/innovent-announces-nmpa-acceptance-of-nda-for-picankibart-anti-il-dpt16kwxl3ok.html
14. IBI112, a selective anti-IL23p19 monoclonal antibody, displays high ..., accessed August 29, 2025, https://pubmed.ncbi.nlm.nih.gov/33069927/
15. Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review - PMC - PubMed Central, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9928578/
16. What is Picankibart used for? - Patsnap Synapse, accessed August 29, 2025, https://synapse.patsnap.com/article/what-is-picankibart-used-for
17. Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint - PR Newswire, accessed August 29, 2025, https://www.prnewswire.com/news-releases/innovent-announces-phase-2-clinical-study-of-picankibart-ibi112-in-chinese-patients-with-moderate-to-severe-plaque-psoriasis-met-primary-endpoint-301602419.html
18. Press Release, accessed August 29, 2025, https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=343
19. Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis - PR Newswire, accessed August 29, 2025, https://www.prnewswire.com/news-releases/innovent-announces-first-patient-dosed-in-a-phase-3-clinical-trial-clear-of-picankibart-anti-il23p19-monoclonal-antibody-in-patients-with-moderate-to-severe-plaque-psoriasis-301747546.html
20. Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies - BioSpace, accessed August 29, 2025, https://www.biospace.com/press-releases/innovent-announces-a-phase-3-study-of-picankibart-anti-il-23p19-antibody-completes-first-participant-dosing-exploring-biologics-switching-treatment-for-psoriasis-patients-with-prior-inadequate-response-to-anti-il-17-antibodies
21. Innovent Biologics begins subject dosing in plaque psoriasis therapy trial, accessed August 29, 2025, https://www.clinicaltrialsarena.com/news/innovent-biologics-plaque-psoriasis/
22. Picankibart Drug Profile - Ozmosi, accessed August 29, 2025, https://pryzm.ozmosi.com/product/22971
23. Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study - PubMed, accessed August 29, 2025, https://pubmed.ncbi.nlm.nih.gov/37358916/
24. picankibart (IBI-112) / Innovent Biologics - LARVOL DELTA, accessed August 29, 2025, https://delta.larvol.com/Products/?ProductId=252ca958-82dc-44d2-8f35-5900b2190c5e
25. Innovent's Picankibart (IBI112) Achieves Phase 3 Clinical Success in Moderate to Severe Plaque Psoriasis - Dermatology Times, accessed August 29, 2025, https://www.dermatologytimes.com/view/innovent-s-picankibart-ibi112-achieves-phase-3-clinical-success-in-moderate-to-severe-plaque-psoriasis
26. Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies - PR Newswire, accessed August 29, 2025, https://www.prnewswire.com/news-releases/innovent-announces-a-phase-3-study-of-picankibart-anti-il-23p19-antibody-completes-first-participant-dosing-exploring-biologics-switching-treatment-for-psoriasis-patients-with-prior-inadequate-response-to-anti-il-17-antibodies-302467783.html
27. Innovent's Picankibart Shows Promising Results in Phase 2 Trial for Psoriasis Patients Unresponsive to Previous Biologics - BioPharma APAC, accessed August 29, 2025, https://biopharmaapac.com/news/73/5452/innovents-picankibart-shows-promising-results-in-phase-2-trial-for-psoriasis-patients-unresponsive-to-previous-biologics.html
28. A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy - ClinicalTrials.Veeva, accessed August 29, 2025, https://ctv.veeva.com/study/a-study-of-switching-to-picankibart-in-chinese-patients-with-plaque-psoriasis-with-an-inadequate-res
29. Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint - PR Newswire, accessed August 29, 2025, https://www.prnewswire.com/apac/news-releases/innovent-announces-phase-2-clinical-study-of-picankibart-ibi112-in-chinese-patients-with-ulcerative-colitis-met-primary-endpoint-302277663.html
30. Innovent to seek Chinese approval for IL-23 psoriasis drug after phase 3 success, accessed August 29, 2025, https://synapse.patsnap.com/article/innovent-to-seek-chinese-approval-for-il-23-psoriasis-drug-after-phase-3-success
31. Innovent's phase 3 study of picankibart for treating moderate to severe plaque psoriasis meets all primary and key secondary endpoints - IGMPI, accessed August 29, 2025, https://igmpi.ac.in/news/clinical-research/innovents-phase-3-study-of-picankibart-for-treating-moderate-to-severe-plaque-psoriasis-meets-all-primary-and-key-secondary-endpoints
32. P62 Efficacy and safety of picankibart in moderate-to-severe plaque psoriasis: a randomized, double-blind, Phase 3 CLEAR-1 trial | British Journal of Dermatology | Oxford Academic, accessed August 29, 2025, https://academic.oup.com/bjd/article/191/Supplement_3/ljae360.092/7916155
33. Innovent's psoriasis treatment picankibart meets all endpoints in Phase III trial, accessed August 29, 2025, https://www.clinicaltrialsarena.com/news/innovent-phase-iii-psoriasis-trial/
34. Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA - PR Newswire, accessed August 29, 2025, https://www.prnewswire.com/news-releases/innovent-announces-picankibart-ibi112-achieved-primary-endpoints-in-a-phase-3-clinical-trial-in-treating-moderate-to-severe-plaque-psoriasis-and-plans-to-submit-nda-to-the-nmpa-302156027.html
35. Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics - PR Newswire, accessed August 29, 2025, https://www.prnewswire.com/news-releases/innovent-announces-results-of-a-phase-2-study-of-picankibart-anti-il-23p19-antibody-in-plaque-psoriasis-showing-efficacy-in-patients-with-prior-inadequate-response-to-il-17-biologics-302289289.html
36. Innovent Reports Phase 2 Results for Picankibart in Plaque Psoriasis Showing Efficacy in IL-17 Biologic Non-Responders - Patsnap Synapse, accessed August 29, 2025, https://synapse.patsnap.com/article/innovent-reports-phase-2-results-for-picankibart-in-plaque-psoriasis-showing-efficacy-in-il-17-biologic-non-responders
37. Innovent, awaiting Chinese regulators' verdict, posts another psoriasis win for IL-23 drug, accessed August 29, 2025, https://www.fiercebiotech.com/biotech/innovent-awaiting-chinese-regulators-verdict-posts-another-psoriasis-win
38. Innovent Biologics' New Drug Application for Picankibart Accepted by China's NMPA for Treatment of Moderate to Severe Plaque Psoriasis - BioPharma APAC, accessed August 29, 2025, https://biopharmaapac.com/news/92/5310/innovent-biologics-new-drug-application-for-picankibart-accepted-by-chinas-nmpa-for-treatment-of-moderate-to-severe-plaque-psoriasis.html
39. Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint - BioSpace, accessed August 29, 2025, https://www.biospace.com/innovent-announces-phase-2-clinical-study-of-picankibart-ibi112-in-chinese-patients-with-moderate-to-severe-plaque-psoriasis-met-primary-endpoint
40. Risankizumab Interactions Checker - Drugs.com, accessed August 29, 2025, https://www.drugs.com/drug-interactions/risankizumab.html
41. Press Release, accessed August 29, 2025, https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=488
42. (PDF) Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis - ResearchGate, accessed August 29, 2025, https://www.researchgate.net/publication/350527817_Comparative_Efficacy_and_Relative_Ranking_of_Biologics_and_Oral_Therapies_for_Moderate-to-Severe_Plaque_Psoriasis_A_Network_Meta-analysis
43. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8163943/
44. Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison | Anais Brasileiros de Dermatologia, accessed August 29, 2025, https://www.anaisdedermatologia.org.br/en-risankizumab-guselkumab-for-psoriasis-1-year-articulo-S0365059624002526
45. New Psoriasis Medications: 11 Drugs Seeking FDA Approval - GoodRx, accessed August 29, 2025, https://www.goodrx.com/conditions/psoriasis/new-psoriasis-medications
46. Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6896234/
47. Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7719363/
48. This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis | ClinicalTrials.gov, accessed August 29, 2025, https://clinicaltrials.gov/study/NCT02772601